- Home
- DTE vs BIIB Comparison
DTE vs BIIB Comparison
Compare DTE & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTE
- BIIB
- Stock Information
- Founded
- DTE 1903
- BIIB 1978
- Country
- DTE United States
- BIIB United States
- Employees
- DTE N/A
- BIIB N/A
- Industry
- DTE Electric Utilities: Central
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- DTE Utilities
- BIIB Health Care
- Exchange
- DTE Nasdaq
- BIIB Nasdaq
- Market Cap
- DTE 26.1B
- BIIB 25.1B
- IPO Year
- DTE N/A
- BIIB 1991
- Fundamental
- Price
- DTE $121.18
- BIIB $149.34
- Analyst Decision
- DTE Buy
- BIIB Buy
- Analyst Count
- DTE 16
- BIIB 26
- Target Price
- DTE $131.38
- BIIB $248.00
- AVG Volume (30 Days)
- DTE 1.4M
- BIIB 1.6M
- Earning Date
- DTE 02-06-2025
- BIIB 02-11-2025
- Dividend Yield
- DTE 3.61%
- BIIB N/A
- EPS Growth
- DTE 21.85
- BIIB 10.05
- EPS
- DTE 7.38
- BIIB 11.06
- Revenue
- DTE $12,415,000,000.00
- BIIB $9,607,500,000.00
- Revenue This Year
- DTE $2.48
- BIIB N/A
- Revenue Next Year
- DTE $2.50
- BIIB N/A
- P/E Ratio
- DTE $16.37
- BIIB $13.47
- Revenue Growth
- DTE N/A
- BIIB N/A
- 52 Week Low
- DTE $102.17
- BIIB $145.07
- 52 Week High
- DTE $131.67
- BIIB $268.30
- Technical
- Relative Strength Index (RSI)
- DTE 46.57
- BIIB 31.81
- Support Level
- DTE $116.65
- BIIB $145.07
- Resistance Level
- DTE $120.81
- BIIB $149.92
- Average True Range (ATR)
- DTE 1.98
- BIIB 3.57
- MACD
- DTE -0.02
- BIIB 0.18
- Stochastic Oscillator
- DTE 63.32
- BIIB 22.27
About DTE DTE Energy Company
DTE Energy owns two regulated utilities in Michigan that contribute 90% of earnings. DTE Electric serves approximately 2.3 million customers in southeastern Michigan, including Detroit. DTE Gas serves 1.3 million customers throughout the state. In addition, DTE has nonutility businesses and investments including energy marketing and trading, renewable natural gas facilities, and on-site industrial energy projects.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.